In future studies, we plan to expand the sample size and consider multicenter cooperation, extend patient follow‐up time, compare serum YKL‐40 levels before and after anti‐VEGF treatment, and provide more reliable evidence for YKL‐40 in the diagnosis and treatment of wet AMD. This evidence concerns the gene CHI3L1 and wet macular degeneration.